Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $36,486.80 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 1,162 shares of Exelixis stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the sale, the executive vice president now owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Dana Aftab also recently made the following trade(s):

• On Monday, August 12th, Dana Aftab sold 20,883 shares of Exelixis stock. The shares were sold at an average price of $27.06, for a total transaction of $565,093.98.
• On Wednesday, August 7th, Dana Aftab sold 95,000 shares of Exelixis stock. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00.

Exelixis Stock Up 2.8 %

Shares of NASDAQ:EXEL traded up $0.92 during midday trading on Friday, reaching $34.12. The company had a trading volume of 4,537,134 shares, compared to its average volume of 2,070,353. Exelixis, Inc. has a 1-year low of $19.20 and a 1-year high of $34.45. The stock has a market cap of $9.74 billion, a PE ratio of 21.28, a P/E/G ratio of 0.69 and a beta of 0.54. The business’s 50 day moving average price is $26.96 and its 200 day moving average price is $24.21.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. The firm had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 EPS. On average, research analysts expect that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Institutional Trading of Exelixis

Large investors have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC bought a new stake in shares of Exelixis in the 3rd quarter valued at about $30,000. Park Place Capital Corp bought a new stake in Exelixis in the second quarter valued at approximately $45,000. GAMMA Investing LLC boosted its stake in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 1,041 shares during the period. EntryPoint Capital LLC increased its holdings in shares of Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,746 shares during the last quarter. Finally, Capital Performance Advisors LLP acquired a new position in shares of Exelixis during the 3rd quarter worth approximately $61,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the topic of several research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Exelixis in a research note on Wednesday. Morgan Stanley raised their price target on Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, October 11th. Bank of America boosted their price objective on Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Truist Financial raised their target price on shares of Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Piper Sandler lifted their price target on shares of Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.44.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.